76 related articles for article (PubMed ID: 12860502)
1. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.
Donnelly D; Pillinger KE; Debnath A; DePasquale W; Munsiff S; Louie T; Jones CMC; Shulder S
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S40-S48. PubMed ID: 38465838
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study.
Alghanem SS; Soliman MM; Al-Manie S; Alfouzan W; Alhammadi D; Alreshidi Y; Hajjiah A; Alfarhoud R; Almane M; Mataqi M; Alajmi S; Albenwan K
Saudi Pharm J; 2023 Nov; 31(11):101813. PubMed ID: 37860688
[TBL] [Abstract][Full Text] [Related]
3. Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study.
Gauzit R; Kabir-Ahmadi M; Thompson N; Pea F; Tattevin P
Int J Antimicrob Agents; 2023 Oct; 62(4):106940. PubMed ID: 37524134
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin: a novel antimicrobial.
Chen AY; Zervos MJ; Vazquez JA
Int J Clin Pract; 2007 May; 61(5):853-63. PubMed ID: 17362476
[TBL] [Abstract][Full Text] [Related]
5. A cost minimisation analysis comparing oral linezolid and intravenous daptomycin administered via an outpatient parenteral antibiotic therapy programme in patients requiring prolonged antibiotic courses.
Faller E; Jackson A
J Chemother; 2023 Sep; 35(5):411-424. PubMed ID: 36398996
[TBL] [Abstract][Full Text] [Related]
6. Gram-stain-based antimicrobial selection reduces cost and overuse compared with Japanese guidelines.
Taniguchi T; Tsuha S; Shiiki S; Narita M
BMC Infect Dis; 2015 Oct; 15():458. PubMed ID: 26503359
[TBL] [Abstract][Full Text] [Related]
7. Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.
Veerman K; Goosen J; Spijkers K; Jager N; Heesterbeek P; Telgt D
J Antimicrob Chemother; 2023 Nov; 78(11):2660-2666. PubMed ID: 37681570
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin: a new option for systemic treatment of Gram-positive endogenous endophthalmitis?
Hamon A; Benaboud S; Anjou M; Thoreau B; Dedieu D; Brezin A; Froelicher Bournaud L; Tazi A; Charlier C; Canouï E
J Antimicrob Chemother; 2023 Dec; 78(12):3005-3006. PubMed ID: 37812460
[No Abstract] [Full Text] [Related]
9. Methods to Reduce Cost of Treatment in Childhood Bone and Joint Infection: A Systematic Review.
Hunter S; Crawford H; Ao BT; Grant C
JBJS Rev; 2024 May; 12(5):. PubMed ID: 38814570
[TBL] [Abstract][Full Text] [Related]
10. Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess.
Yoong J; Yuen KH; Molton JS; Ding Y; Cher BP; Chan M; Kalimuddin S; Oon J; Young B; Low J; Salada BMA; Lee TH; Wijaya LM; Fisher D; Izharuddin E; Wei Y; Phillips R; Moorakonda R; Lye DC; Archuleta S
Sci Rep; 2023 Jun; 13(1):9774. PubMed ID: 37328522
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial.
McCarthy MW; Keyloun KR; Gillard P; Choi JJ; Pickell N; Copp R; Walsh TJ
Infect Dis Ther; 2020 Mar; 9(1):53-67. PubMed ID: 31713130
[TBL] [Abstract][Full Text] [Related]
12. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Adjuvant Clindamycin vs Linezolid for Severe Invasive Group A
Heil EL; Kaur H; Atalla A; Basappa S; Mathew M; Seung H; Johnson JK; Schrank GM
Open Forum Infect Dis; 2023 Dec; 10(12):ofad588. PubMed ID: 38149106
[TBL] [Abstract][Full Text] [Related]
14. It is premature to reduce linezolid doses in patients with impaired kidney function.
Maves RC
Clin Infect Dis; 2023 Dec; ():. PubMed ID: 38113482
[No Abstract] [Full Text] [Related]
15. The determinants of the antibiotic resistance process.
Franco BE; Altagracia Martínez M; Sánchez Rodríguez MA; Wertheimer AI
Infect Drug Resist; 2009; 2():1-11. PubMed ID: 21694883
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.
Grau S; Mateu-de Antonio J; Soto J; Marín-Casino M; Salas E
Pharm World Sci; 2005 Dec; 27(6):459-64. PubMed ID: 16341954
[TBL] [Abstract][Full Text] [Related]
17. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2005; 23(9):945-64. PubMed ID: 16153136
[TBL] [Abstract][Full Text] [Related]
18. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
